High levels of immuno-inflammatory markers predicts unfavorable short-term outcomes in patients with acute ischemic stroke

CURRENT STATUS: UNDER REVIEW

Journal of Neuroinflammation

Shinn-Kuang Lin
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

stuartlin0428@gmail.com
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8711-5008

Pei-Ya Chen
Taipei Tzu Chi Hospital

Guei-Chiuan Chen
Taipei Tzu Chi Hospital

Po-Jen Hsu
Taipei Tzu Chi Hospital

Cheng-Lun Hsiao
Taipei Tzu Chi Hospital

Fu-Yi Yang
Taipei Tzu Chi Hospital

Chih-Yang Liu
Taipei Tzu Chi Hospital

Adam Tsou
Taipei Tzu Chi Hospital

Yu-Chin Su
Taipei Tzu Chi Hospital

DOI: 10.21203/rs.3.rs-19523/v1

SUBJECT AREAS
Neurobiology of Disease
KEYWORDS

acute ischemic stroke, neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, systemic immune-inflammation index, unfavorable outcome
Abstract

Background

Atherosclerosis is a chronic inflammatory process that occurs in the arterial wall. This immuno-inflammatory process plays a role throughout all stages of stroke. Neutrophils, lymphocytes, and platelets are crucial blood cells for innate and adaptive immunity. This study investigated the associations of four types of immuno-inflammatory markers, namely the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and neutrophil count (NC), with clinical outcomes in patients with acute ischemic stroke.

Methods

In this retrospective study, we enrolled 2903 inpatients with acute ischemic stroke from May 2010 to May 2019. Data included risk factors, laboratory parameters, and clinical features during hospitalization. The National Institutes of Health Stroke Scale (NIHSS), and modified Rankin Scale (mRS) were used to assess stroke severity and outcomes.

Results

All four immuno-inflammatory markers exhibited positive linear correlations with age, glucose, creatinine, length of hospital stay, NIHSS score on admission, and mRS score at discharge. The levels of the four immuno-inflammatory markers were significantly higher in patients with large-artery atherosclerosis and cardioembolism and were highest in patients with other determined etiology. Patients with levels of immuno-inflammatory markers higher than their cutoff values for unfavorable outcomes also exhibited higher rates of cancer history (except for SII and NC), uremia (except for NC), elevated troponin I, and in-hospital complications. Multivariate analysis including SII revealed that admission NIHSS score ≥ 5, age > 75 years, SII > 724, diabetes mellitus, female sex, elevated troponin I, heart disease, and prior stroke were significant predictors for unfavorable outcomes. These significant predictors were retained after replacing SII > 724 with NLR > 143, PLR > 3.5, or NC > 6 × 10^3 /mL, except for prior stroke. For a basic model comprising seven significant predictors of unfavorable outcomes, the C-statistic was 0.860. The addition of SII, NLR, and PLR to the basic model resulted in a significant improvement in the prediction performance to 0.864, 0.863, and 0.863,
Conclusions

Immuno-inflammatory markers provide more useful information than conventional risk factors and other laboratory parameters for the prediction of stroke outcomes. SII > 724 is the most appropriate marker when combined with other predictors.

Introduction

Stroke was the fourth leading cause of death in Taiwan from 2000 to 2020, and it is the leading cause of prolonged disability among older adults. Traditional risk factors for vascular diseases, such as old age, hypertension, diabetes mellitus, and heart disease, are prominent comorbidities of stroke. Most previous studies have emphasized the correlation of these comorbidities with stroke and clinical outcomes. The clinical feature of initial stroke severity has been reported to be a strong predictor of functional outcomes [1, 2]. Laboratory parameters during acute stroke, such as hemoglobin level [3], blood urea nitrogen-to-creatinine ratio [4], and troponin I level [5], also provide valuable information when investigating clinical outcomes after stroke. Atherosclerosis is a chronic inflammatory process that occurs in the arterial wall [6]. Immunity and inflammation have been recognized as crucial elements of the pathobiology of stroke. Immuno-inflammatory processes play roles throughout all stages of acute stroke, including initial arterial occlusion, brain parenchymal damage, subsequent tissue repair, and infectious complications [7].

Innate and adaptive systems are two main types of immune systems. Innate immunity refers to the immune responses present at birth, and this provides first rapid defense against invasion. Innate immunity is mainly provided by neutrophils, monocytes, macrophages, natural killer cells, and complement systems [8]. Adaptive immunity, also known as acquired immunity, is provided by lymphocytes, which deliver antigen-dependent and antigen-specific responses to invasion. Recent studies have suggested that platelets not only mediate hemostasis and thrombosis but also participate in immuno-inflammatory responses by promoting innate effector cell functions and enhancing adaptive immune responses [9, 10]. To clarify the associations between immuno-inflammatory responses and outcomes of acute stroke, several clinical studies have investigated
neutrophils, lymphocytes, and platelets. Detection of a single cellular line may be insufficient to recognize the status and complexity of the immune system. Moreover, a single blood cell test can be influenced by conditions such as overhydration, dehydration, and the treatment of blood specimens [11]. Ratios of cell measurements, such as the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), are considered suitable for reflecting the balance between innate and adaptive immunity [12]. Higher neutrophil count (NC), NLR, and PLR have been reported to be associated with poor outcomes among patients with acute stroke and patients with various types of cancer [11, 13-16]. Hu et al. developed a novel systemic immune-inflammation index (SII) based on platelet, neutrophil, and lymphocyte counts, and they found that SII was a powerful indicator of poor outcomes among patients with hepatocellular carcinoma [17]. Similarly, other studies have reported that higher SII is associated with deterioration in cancer, endocarditis, and dementia [12, 18, 19]. However, the correlation of SII with stroke outcomes has rarely been explored. In the present study, we aimed to investigate the association of four immuno-inflammatory markers, namely SII, NLR, PLR, and NC, with clinical outcomes in patients with acute ischemic stroke. We also compared the predictive performance of these four markers.

Materials & Methods

Study Population and Data Collection

The stroke registry database was retrospectively reviewed to identify patients who were treated for stroke in a neurological ward from May 2010 to May 2019. Inclusion criteria were 1) diagnosis of acute ischemic stroke confirmed by clinical presentation and 2) proof of an ischemic lesion or absence of a corresponding intracranial lesion other than infarction according to brain computed tomography or magnetic resonance imaging. Sex, age, history of hypertension, diabetes mellitus, hyperlipidemia, heart disease, prior stroke, smoking status, alcohol consumption, cancer, uremia, and length of stay (LOS) in hospital were recorded for analysis. Laboratory data obtained on arrival in the emergency department included full blood count with white blood cell differentials as well as platelet, glucose, creatinine, and troponin I levels. Abnormal elevation of troponin I was defined as a blood troponin I level > 0.01 μg/L; troponin I level was registered as 0.01 μg/L if the patient had a value of ≤ 0.01
μg/L. Fasting cholesterol and triglyceride were recorded during the morning after admission to the ward.

**Stroke Severity and Clinical Features**

Stroke severity was assessed on admission according to the National Institutes of Health Stroke Scale (NIHSS). We classified the etiology of ischemic stroke according to the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) categories, namely large-artery atherosclerosis, small-vessel occlusion, cardioembolism, other determined etiology, and undetermined etiology [20]. Urinary tract infection, pneumonia, gastrointestinal bleeding, and seizure were registered as in-hospital stroke complications. Functional outcomes were evaluated using the NIHSS, the Barthel index and the modified Rankin Scale (mRS) at discharge. An mRS score > 2 was considered to indicate an unfavorable outcome.

**Definition of Immuno-inflammatory Markers**

Four immuno-inflammatory markers, namely SII, NLR, PLR, and NC, were obtained for analysis. The NLR and PLR were calculated as the ratio of neutrophil count to lymphocyte count and the ratio of platelet count to lymphocyte count, respectively. SII was calculated as the platelet count multiplied by the NLR. For patients admitted to the ward with transient ischemic attack (TIA) during the same period, these immuno-inflammatory markers were also collected for comparison.

**Statistical Analysis**

Continuous variables are presented as mean ± standard deviation. The chi-square test and Fisher’s exact test were used for categorical comparisons. Group comparisons of continuous variables were performed using two-sample t tests or analysis of variance as appropriate. Significant predictors in the univariate analyses that were continuous variables were converted into dichotomous variables, with the optimal cutoff level determined according to the Youden index by using receiver operating characteristic (ROC) curve for unfavorable outcomes. The variables were then added to a multiple logistic regression model to identify the significant factors associated with unfavorable outcomes. We compared the predictive performance of the variables by using the C-statistic for unfavorable outcomes. A p value of less than 0.05 was considered to indicate a significant result. All statistical analyses were performed with SPSS (Version 24, SPSS Inc, Chicago, IL, USA). The ROC curves were
compared using the MedCalc software package (version 18, Mariakerke, Belgium). This study was approved by the Institutional Review Board of Taipei Tzu Chi Hospital (09-X-025).

Results
During the study period, 2903 patients with acute ischemic stroke and 457 patients with TIA were enrolled. Of the 2903 patients with acute ischemic stroke, 2036 patients (70%) had valid data concerning troponin I levels because troponin I was not routinely measured in the emergency department for patients with acute stroke during that period. The average age of patients with acute ischemic infarct and patients with TIA were 71.0 ± 13.5 and 70.5 ± 13.2 years, respectively. Table 1 shows the clinical characteristics of the 2903 patients with acute ischemic stroke and the sex differences for these characteristics. The average values of SII, NLR, PLR, and NC were 892 ± 1354, 4.2 ± 56, 145 ± 119, and 5.6 ± 2.6 × 10^{3}/mL, respectively. Female patients tended to be older than their male counterparts; they had higher platelet count, SII, PLR, cholesterol, LOS in hospital, NIHSS on admission, and mRS at discharge; and they had higher rates of heart disease, history of cancer, and in-hospital complications. Male patients had higher levels of hemoglobin, creatinine, and triglyceride than their female counterparts, as well as higher rates of prior stroke, smoking, and alcohol consumption. Table 2 shows correlations of the four immuno-inflammatory markers with the measured variables. All of the immuno-inflammatory markers exhibited similar linear correlations with the measured variables, including positive correlations with age, glucose level, creatinine level, LOS in hospital, NIHSS on admission, NIHSS at discharge, and mRS at discharge; negative correlations were observed with hemoglobin level, triglyceride level (except for NC), and Barthel index at discharge. By using ROC curve analysis, we identified cutoff points for the immuno-inflammatory markers to indicate unfavorable outcomes (i.e., mRS >2). The cutoff points for SII, NLR, PLR, and NC were 724, 3.5, 143, and 6 × 10^{3}/mL, respectively. Patients with SII, NLR, PLR, and NC higher than cutoff values also had higher rates of history of cancer (except for SII and NC), uremia (except for NC), elevated troponin I level, in-hospital complications, and unfavorable outcomes (Table 2).

We compared the levels of the four immuno-inflammatory markers in the five groups categorized according to the TOAST classifications and patients with TIA; this comparison revealed the same
results (Table 3). Patients with cardioembolism tended to be older and the highest initial NIHSS scores, whereas patients with small-vessel disease had the lowest initial NIHSS scores. No difference was observed in the levels of the four immuno-inflammatory markers between patients with TIA and those with small-vessel disease, or between those with large-artery atherosclerosis and those with cardioembolism. Levels of the four markers were significantly higher in patients with large-artery atherosclerosis, cardioembolism, and other determined etiology compared with other patients ($p \leq 0.002$). The highest levels of these markers were observed in patients with other determined etiology. Univariate analyses of continuous variables revealed that older age; higher levels of white blood cell counts, SII, NLR, PLR, NC, and creatinine; longer LOS in hospital; higher NIHSS on admission; and lower levels of hemoglobin, cholesterol, and triglyceride were significantly associated with unfavorable outcomes (Table 4). Univariate analyses of dichotomous variables revealed that female sex, hypertension, diabetes mellitus, heart disease, prior stroke, history of cancer, uremia, elevated troponin I level, and in-hospital complications were significant positive predictors of unfavorable outcomes. However, hyperlipidemia, smoking status, and alcohol consumption were positive predictors of favorable outcomes.

Table 5 presents the regression analysis for the effect of the main significant factors in Table 4 on unfavorable outcomes; the optimal cutoff values for age (75 years) and admission NIHSS score (5) were determined according to the ROC curve. The four immuno-inflammatory markers were included separately in each analysis. Multivariate logistic regression analysis including SII revealed that admission NIHSS score $\geq 5$ (odds ratio [OR]: 13.934; 95% confidence interval [CI]: 11.001–17.648; $p < 0.001$), age $> 75$ years (OR: 2.650; 95% CI: 2.067–3.399; $p < 0.001$), SII $> 724$ (OR: 1.808; 95% CI: 1.422–2.297; $p < 0.001$), diabetes mellitus (OR: 1.561; 95% CI: 1.214–2.008; $p < 0.001$), elevated troponin I level (OR: 1.875; 95% CI: 1.272–2.765; $p = 0.002$), female sex (OR: 1.403; 95% CI: 1.088–1.809; $p = 0.009$), heart disease (OR: 1.340; 95% CI: 1.038–1.729; $p = 0.0258$), and prior stroke (OR: 1.316; 95% CI: 1.008–1.717; $p = 0.043$) were significant predictors of unfavorable outcomes. These same significant predictors were identified in multivariate logistic regression analyses when SII was replaced with NLR (OD: 1.761; 95% CI: 1.382–2.243; $p < 0.001$), PLR (OD: 1.600; 95% CI: 1.254–
The C-statistics of the regression models for the detection of unfavorable outcomes are shown in Table 6 for each predictor. We established a basic model comprising the seven significant predictors of admission NIHSS $\geq$ 5, age $>$ 75 years, diabetes mellitus, elevated troponin I level, female sex, heart disease, and prior stroke. The C-statistic for this basic model was 0.860 (Figure 1). The addition of SII to the basic model resulted in a significant improvement in the C-statistic from 0.860 to 0.864 ($p = 0.038$; Table 6). The addition of NLR or PLR to the basic model also resulted in significant improvements of the C-statistic from 0.860 to 0.863 ($p = 0.042$ and 0.048 for NLR and PLR, respectively). Including NC in the basic model improved the C-statistic from 0.860 to 0.861, but the difference was not significant. The simultaneous addition of all four immuno-inflammatory markers to the basic model resulted in a significant improvement of the C-statistic to 0.864 ($p = 0.032$); the addition of all markers did not result in a stronger predictive performance than addition of SII alone.

Discussion
Sex differences in the risk factor distribution, severity, and outcomes of ischemic stroke are multifactorial and related to genetics, environmental factors, and social influences [21–23]. Previous studies have revealed that older women with higher stroke severity at stroke onset have higher platelet counts, higher prevalence of cardioembolism, and more unfavorable clinical outcomes. Similar results were observed in the present study. Furthermore, we found that women had higher SII and PLR, as well as higher rates of cancer history, elevated troponin I level, and in-hospital complications. No differences in NLR and NC were observed between male and female patients, possibly due to absence of platelet count in these markers. Recent studies have revealed that risk of stroke not only increases after a new cancer diagnosis but also increases with time in almost all cancer survivors [24, 25]. Cancer and related therapies may cause coagulopathies, such as nonbacterial thrombotic endocarditis, alterations in platelet and endothelial function, and radiation-induced atherosclerosis. Elevated troponin I level during acute stroke is a strong independent predictor for both unfavorable outcomes and in-hospital mortality. The mechanisms of elevated troponin I level during acute stroke include ischemic myocardial injury, neurogenic heart syndrome
through increased sympathetic activity causing cardiomyopathy, and other systemic conditions such as infection, sepsis, renal failure, and pulmonary embolism [5].

Atherosclerosis is the primary underlying pathological process in coronary and cerebral arterial diseases; it is considered as a chronic inflammation that causes large and medium arterial thromboses [26]. The innate and adaptive immune mechanisms are both involved in the prothrombotic progression of atherosclerotic change. When acute ischemic stroke occurs during arterial occlusion, the inflammatory response following the release of danger signals from damaged brain tissue leads to an activation of immune system. Innate immunity, including neutrophils, monocytes, macrophages, platelet, and dendritic cells, is rapidly activated with the production of various cytokines. This is followed by activation of the adaptive immunity, namely lymphocytes, which exerts an immunosuppressive effect that promotes intercurrent infections (i.e., stroke-induced immunodepression) [7]. These immunological changes may last for weeks and may increase the risk of respiratory or urinary tract infections, particular among patients with severe stroke, thus affecting clinical outcomes [27]. Neutrophils, which are secretory and phagocytic cells, migrate to the intraparenchymal perivascular areas within several hours after cerebral ischemia and participate in the early destruction of the blood–brain barrier [28]. Higher NC indicates a larger area of ischemia and more severe brain damage. Lymphocytes, which mainly comprise humoral immune response B cells and cellular immunity T cells, accumulate in the brain 3–6 days after stroke and are considered as having a regulatory function by inducing neuroprotection. Persistent lymphopenia after stroke, caused by the redistribution of lymphocytes to the lymphatic organs and increased catecholamine and cortisol levels, indicates prolonged brain damage with a higher stress response, and this is associated with unfavorable long-term prognosis [29]. In addition to promoting the progression of atherosclerosis, platelets release mediators to boost inflammation after stroke and result in the release of neutrophils and lymphocytes into the vessel wall. For patients with cancer, neutrophils and platelets have also been observed to promote cancer cell proliferation, invasion, immune evasion, and metastasis through multiple mechanisms. Therefore, elevated levels of inflammatory markers are considered to indicate a substantial tumor burden and an ongoing chronic inflammatory process [30].
In the present study we found that all four immuno-inflammatory markers were positively correlated with age, glucose level, creatinine level, NIHSS on admission, LOS in hospital, and mRS at discharge. Patients whose immuno-inflammatory markers were higher than the cutoff values for unfavorable outcomes also exhibited higher rates of uremia, elevated troponin I level, and in-hospital complications. Higher NLR and PLR have been reported in patients with type 2 diabetes mellitus and hyperglycemia, respectively [31, 32]. Although previous studies have suggested that these immuno-inflammatory markers were increased among patients with various cancers, we did not identify any differences among stroke patients with and without a history of cancer, possibly because these cancers were inactive or cured. Cholesterol level had an inverse correlation with age and immuno-inflammatory markers, and it was lower in patients with unfavorable outcomes. This result was similar to that revealed by Fang et al., who identified that high total cholesterol was significantly and independently predictive of lower NIHSS and less severe stroke [13]. Older adults tending to have diets with low lipid content or experiencing malnutrition due to chewing disorders may explain this finding. Higher immuno-inflammatory markers indicated a higher severity of stroke and a less favorable immune status, which resulted in more in-hospital complications, such as pneumonia and urinary tract infections, and prolonged LOS in hospital. The levels of immuno-inflammatory markers varied between the etiologies of stroke according to TOAST classification. Patients with TIA and small-vessel disease had the lowest levels of these markers; this was due to the minor level of stroke severity and the small extent of brain tissue damage from small-artery occlusion. Notably, patients with other determined etiology of stroke, who tended to be younger and have minor degrees of stroke severity relative to those with large-artery atherosclerosis and cardioembolism, exhibited the highest levels of immuno-inflammatory markers. These results differ slightly from those of Gökhan et al., who revealed that NLR was lowest among patients with TIA and highest among those with large-artery occlusion [29]. Other determined etiology in the TOAST classification was classified as rare stroke type in the study by Gökhan et al., and no patient was assigned to the rare stroke subtype. In the present study, 43 patients were assigned to the other determined etiology group. Most of these patients had prominent immunological, hematological, or systemic disorders associated with acute
stroke. Therefore, immuno-inflammatory markers were considerably higher in these patients. Several concomitant comorbidities, clinical features, and laboratory parameters were associated with unfavorable short-term outcomes during univariate analyses. Significant predictors of unfavorable outcomes in the multivariate analyses were NIHSS on admission ≥ 5, age > 75 years, diabetes mellitus, elevated troponin I level, female sex, heart disease, prior stroke, and the four immuno-inflammatory markers (SII > 724, NLR > 3.5, PLR > 143, and NC > 6 × 10^3/mL). Among these, NIHSS on admission ≥ 5 had the highest OR for unfavorable outcomes (13.4–14.2), followed by age > 75 years (2.5–2.8), and the four immuno-inflammatory markers (1.6–1.8). The predictive performance for unfavorable outcomes was similar when using SII, NLR, and PLR, whereas the performance of NC was slightly weaker. Because the four markers were derived from white blood cell counts with or without platelet counts, which are essential laboratory data during acute stroke and common routine examinations, we can choose one as a reference marker for the prediction of unfavorable outcomes. SII > 724 is the most appropriate marker because this provided the optimal predictive performance of 0.864 when combined with the other seven predictors.

This study had several limitations. First, this was a retrospective study. We did not have sufficient sequential data during hospitalization for a dynamic comparison of immuno-inflammatory markers. A dynamic increase in NLR has been reported to predict 3-month mortality or major disability among patients receiving intravenous thrombolytic treatment [33]. Second, we did not investigate the association between infarct volume and the immuno-inflammatory markers. However, the TOAST classifications may partly reflect the infarct size. Third, because we did not perform a follow-up study after discharge, only short-term outcomes at discharge were available. A prospective study with serial immuno-inflammatory markers and long-term outcomes may provide more prognostic relevance for acute ischemic stroke. Notwithstanding these limitations, the results extend the current understanding of the implications of immuno-inflammatory markers among patients with acute ischemic stroke.

**Conclusion**

Initial stroke severity (NIHSS on admission ≥ 5) and age (age > 75 years) are the two most significant
predictors of unfavorable outcome among patients with acute ischemic stroke. Immuno-inflammatory markers including SII, NLR, PLR, and NC provide improved prediction of stroke outcomes compared with conventional risk factors and laboratory parameters. SII > 724 is the most appropriate marker because it provided the optimum predictive performance of up to 0.864 when combined with other predictors.

Abbreviations
CI: confidence interval; LOS: length of stay; mRS: modified Rankin Scale; NC: neutrophil count; NIHSS: National Institutes of Health Stroke Scale; NLR: neutrophil-to-lymphocyte ratio; OD: odds ratio; PLR: platelet-to-lymphocyte ratio; ROC: receiver operating characteristic; SII: systemic immune-inflammation index; TOAST: Trial of ORG 10172 in Acute Stroke Treatment; TIA: transient ischemic attack

Declarations

Acknowledgements
Not applicable.

Authors’ contributions
PA, GC, PJ, CL, FY, CY, AT, and YC participated in taking care of patients and acquisition of data. SK designed the study, conducted data analysis, drafted the initial manuscript, prepared the tables, and revised the manuscript. All authors have contributed to manuscript revision, read, and approved the submitted version.

Funding
This study was funded by Taipei Tzu Chi Hospital (TCRD-TPE-109-RT-7). The founder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the Institutional Review Board of Taipei Tzu Chi Hospital (09-X-025).
Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Stroke Center and Department of Neurology, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan.

2 School of Medicine, Tzu Chi University, Hualien, Taiwan.

References

1. Sato S, Toyoda K, Uehara T, Toratani N, Yokota C, Moriwaki H, et al. Baseline NIH stroke scale score predicting outcome in anterior and posterior circulation strokes. Neurology. 2008;70:2371–7.

2. Rost NS, Bottle A, Lee JM, Randall M, Middleton S, Shaw L, et al. Stroke severity is a crucial predictor of outcome: an international prospective validation study. J Am Heart Assoc. 2016;5:e002433.

3. Barlas RS, Honney K, Loke YK, McCall SJ, Bettencourt-Silva JH, Clark AB, et al. Impact of hemoglobin levels and anemia on mortality in acute stroke: analysis of UK regional registry data, systematic review, and meta-analysis. J Am Heart Assoc. 2016;5:e003019.

4. Schrock JW, Glasenapp M, Drogell K. Elevated blood urea nitrogen/creatinine ratio is associated with poor outcome in patients with ischemic stroke. Clin Neurol Neurosurg. 2012;114:881-4.

5. Su YC, Huang KF, Yang FY, Lin SK. Elevation of troponin I in acute ischemic stroke. PEERJ. 2016;11:e1866.

6. Massiot N, Lareyre F, Voury-Pons A, Pelletier Y, Chikande J, Carboni J, et al. High
neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are associated with symptomatic internal carotid artery stenosis. J Stroke Cerebrovas Dis. 2019;28:76-83.

7. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796-808.

8. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003;7:23-38.

9. Ali RA, Wuescher LM, Worth RG. Platelets: essential components of the immune system. Curr Trends Immunol. 2015;16:65–78.

10. Ponomarev ED. Fresh evidence for Platelets as neuronal and innate immune cells: their role in the activation, differentiation, and deactivation of Th1, Th17, and Tregs during tissue inflammation. Front Immunol. 2018;9:406.

11. Xu JH, He XW, Li Q, Liu JR, Zhuang MT, Huang FF, et al. Higher platelet-to-lymphocyte ratio is associated with worse outcomes after intravenous thrombolysis in acute ischaemic stroke. Front Neurol. 2019;10:1192.

12. Van der Willik KD, Fani L, Rizopoulos D, Licher S, Fest J, Schagen SB, et al. Balance between innate versus adaptive immune system and the risk of dementia: a population-based cohort study. J Neuroinflamm. 2019;16:68.

13. Fang YN, Tong MS, Sung PH, Chen YL, Chen CH, Tsai NW, et al. Higher neutrophil counts and neutrophil-to-lymphocyte ratio predict prognostic outcomes in patients after non-atrial fibrillation-caused ischemic stroke. Biomed J. 2017;40:154-62.

14. Lim HH, Jeong IH, An GD, Woo KS, Kim KH, Kim JM, et al. Early prediction of severity in acute ischemic stroke and transient ischemic attack using platelet parameters and neutrophil-to-lymphocyte ratio. J Clin Lab Anal. 2019;33:e22714.

15. Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y, Kita Y, et al. Combined
neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts chemotherapy response and prognosis in patients with advanced gastric cancer. BMC Cancer. 2019;19:672.

16. HUSZNO J, KOLOSZA Z. Prognostic value of the neutrophil-lymphocyte, platelet-lymphocyte and monocyte-lymphocyte ratio in breast cancer patients. Oncol Lett. 2019;18: 6275-83.

17. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res. 2014;20;6212-22.

18. Fest J, Ruiter R, Mulder M, Koerkamp BG, Ikram MA, Stricker BH, et al. The systemic immune-inflammation index is associated with an increased risk of incident cancer – a population-based cohort study. Int J Cancer. 2020;146,692–8.

19. Agus HZ, Kahraman S, Arslan C, Yildirim C, Erturk M, Kalkan AK, et al. Systemic immune-inflammation index predicts mortality in infective endocarditis. J Saudi Heart Assoc. 2020; doi:10.1016/j.jsha.2019.11.001.

20. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke. 1993;24:35-41.

21. Giralt D, Domingues-Montanari S, Mendioroz M, Ortega L, Maisterra O, Perea-Gainza M, et al. The gender gap in stroke: a meta-analysis. Acta Neurol Scand. 2012:125:83-90.

22. Santalucia P, Pezzella FR, Sessa M, Monaco S, Torgano G, Anticoli S, et al. Sex differences in clinical presentation, severity and outcome of stroke: Results from a hospital-based registry. Eur J Intern Med. 2013;24:167-71.

23. Ong CT, Wong YS, Sung SF, Wu CS, Hsu YC, Su YH, et al. Sex-related differences in
the risk factors for in-hospital mortality and outcomes of ischemic stroke patients in rural areas of Taiwan. PLoS ONE. 2017;12:e0185361.

24. Navi BB, Reiner AS, Kamel H, Iadecola C, Elkind MSV, Panageas KS, et al. Association between Incident Cancer and Subsequent Stroke. Ann Neurol. 2015;77:291-300.

25. Zaorsky NG, Zhang Y, Tchelebi LT, Mackley HB, Chinchilli VM, Zacharia BE. Stroke among cancer patients. Nat Commun. 2019;10:5172.

26. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12:204-12.

27. Macrez R, Ali C, Toutirais O, Le Mauff B, Defer G, Dirnagl U, et al. Stroke and the immune system: from pathophysiology to new therapeutic strategies. Lancet Neurol. 2011;10:471-80.

28. Zhang R, Wu X, Hu W, Zhao L, Zhao S, Zhang J, et al. Neutrophil-to-lymphocyte ratio predicts hemorrhagic transformation in ischemic stroke: A meta-analysis. Brain Behav. 2019;9:e01382.

29. Gökhan S, Özhasenekler A, Mansur Durgun H, Akil E, Ustündag M, Orak M. Neutrophil lymphocyte ratios in stroke subtypes and transient ischemic attack. Eur Rev Med Pharmacol Sci. 2013;17:653-7.

30. Xie QK, Chen P, Hu WM, Sun P, He WZ, Jiang C, et al. The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor. J Transl Med. 2018;16:273.

31. Guo X, Zhang S, Zhang Q, Liu L, Wu H, Du H, et al. Neutrophil:lymphocyte ratio is positively related to type 2 diabetes in a large-scale adult population: a Tianjin Chronic Low-Grade Systemic Inflammation and Health cohort study. Eur J Endocrinol. 2015;173:217-25.
32. Mendes BB, Oliveira AC, Alcântara KC. Comparison of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in normoglycemic and hyperglycemic subjects. Einstein (São Paulo). 2019;17:1-5.

33. Shi J, Peng H, You S, Liu Y, Xu J, Xu Y, et al. Increase in neutrophils after recombinant tissue plasminogen activator thrombolysis predicts poor functional outcome of ischaemic stroke: a longitudinal study. Eur J Neurol. 2018;25:687-92,e44–45.

Tables

Table 1 Correlation of clinical features with sex in 2903 patients with acute ischemic stroke
| Characteristics                                      | Total (n = 2093) | Gender                              |
|------------------------------------------------------|------------------|-------------------------------------|
|                                                      |                  | Men (n = 1645)                      | Women (n = 1258)                      |
| Mean age (years)                                     | 71.0±13.6        | 68.5±13.6                           | 74.2±12.8                             |
| Hemoglobin (g/dL)                                    | 13.6±2.1         | 14.2±2.0                            | 12.7±1.9                              |
| Platelet (10^9/L)                                    | 212±70           | 204±66                              | 223±74                                |
| White blood cells (x10^3/mL)                         | 8.0±2.8          | 8.1±2.7                             | 8.0±3.0                               |
| Neutrophil counts (x10^3/mL)                         | 5.6±2.6          | 5.6±2.5                             | 5.5±2.8                               |
| Systemic immune inflammation index                   | 892±1354         | 829±862                             | 975±1803                              |
| Neutrophil-to-lymphocyte ratio                       | 4.2±5.6          | 4.1±4.4                             | 4.3±6.8                               |
| Platelet-to-lymphocyte ratio                         | 145±119          | 138±81                              | 156±148                               |
| Troponin I (ug/L)                                    | 0.05±0.35        | 0.04±0.22                           | 0.06±0.47                             |
| Glucose (mg/dL)                                      | 166±80           | 164±77                              | 167±83                                |
| Creatinine (mg/dL)                                   | 1.36±1.17        | 1.45±1.18                           | 1.24±1.16                             |
| Cholesterol (mg/dL)                                  | 170±43           | 167±42                              | 175±44                                |
| Triglyceride (mg/dL)                                 | 123±96           | 126±106                             | 119±81                                |
| Length of stay (days)                                | 14.7±13.6        | 13.8±13.4                           | 16.0±13.8                             |
| NIHSS score on admission                             | 7.6±7.8          | 6.8±7.2                             | 8.7±8.4                               |
| NIHSS score at discharge                             | 7.1±10.1         | 6.2±9.4                             | 8.4±10.7                              |
| Barthel index score at discharge                     | 65±37            | 70±35                               | 59±38                                 |
| modified Rankin Scale at discharge                   | 2.7±1.7          | 2.5±1.7                             | 3.0±1.7                               |
| Hypertension                                         | 2115 (73%)       | 1179 (71%)                          | 936 (74%)                             |
| Diabetes Mellitus                                    | 980 (36%)        | 563 (34%)                           | 417 (37%)                             |
| Hyperlipidemia                                       | 564 (19%)        | 316 (19%)                           | 248 (20%)                             |
| Heart disease                                        | 867 (30%)        | 438 (27%)                           | 429 (34%)                             |
| Prior stroke                                         | 730 (25%)        | 439 (27%)                           | 291 (23%)                             |
| Current smoker                                       | 603 (21%)        | 558 (34%)                           | 45 (4%)                               |
| Alcohol consumption                                  | 230 (8%)         | 224 (14%)                           | 6 (1%)                                |
| History of cancer                                    | 199 (7%)         | 92 (6%)                             | 107 (9%)                              |
| Uremia                                               | 82 (3%)          | 40 (2%)                             | 42 (3%)                               |
| Elevated troponin I                                  | 231/2036 (11%)   | 118/1173 (10%)                      | 113/863 (13%)                         |
| In-hospital complications                            | 444 (16%)        | 204 (12%)                           | 240 (19%)                             |
| modified Rankin Scale > 2 at discharge               | 1479 (51%)       | 734 (45%)                           | 745 (59%)                             |

**Abbreviations:** NIHSS National Institutes of Health Stroke Scale

Data are expressed as mean ± standard deviation or n (%); two sample t or chi-square test
Table 2 Correlation of the four immuno-inflammatory markers with measured variables in 2903 patients

| Variables                      | SII   | NLR   |
|--------------------------------|-------|-------|
| **Linear regression test**     |       |       |
| **coefficient**                | **$R^2$** | **$P$** |     | **coefficient** | **$R^2$** | **$P$** |
| Age                            | 0.0004 | 0.002 | 0.026 | 0.224 | 0.008 | <0.001 |
| Hemoglobin                     | -0.001 | 0.005 | <0.001 | -0.026 | 0.005 | <0.001 |
| Glucose                        | 0.007  | 0.014 | <0.001 | 1.524 | 0.012 | <0.001 |
| Creatinine                     | 0.0005 | 0.004 | <0.001 | 0.015 | 0.005 | <0.001 |
| Cholesterol                    | -0.001 | 0.0005 | 0.260 | -0.527 | 0.005 | <0.001 |
| Triglyceride                   | -0.003 | 0.002 | 0.027 | -1.274 | 0.005 | <0.001 |
| LOS at hospital                | 0.001  | 0.006 | <0.001 | 0.264 | 0.012 | <0.001 |
| NIHSS on admission             | 0.001  | 0.027 | 0.001 | 0.29  | 0.043 | <0.001 |
| NIHSS at discharge             | 0.001  | 0.021 | <0.001 | 0.37  | 0.042 | <0.001 |
| BI at discharge                | -0.04  | 0.028 | <0.001 | -1.434 | 0.047 | <0.001 |
| mRS at discharge               | 0.0002 | 0.025 | <0.001 | 0.063 | 0.042 | <0.001 |

| **Chi-square test**            |   |     |     |   |     |     |
|                               | >724 | ≤724 | **$P$** | >3.5 | ≤3.5 | **$P$** |
| **(n = 1128)**                |     |     |     | (n = 1102) |     |     |
| Female sex                    | 512 (45) | 746 (42) | 0.075 | 469 (43) | 789 (44) | 0.509 |
| History of cancer             | 82 (7) | 117 (7) | 0.496 | 95 (9) | 104 (6) | 0.003 |
| Uremia                        | 45 (4) | 37 (2) | 0.003 | 51 (5) | 31 (2) | <0.001 |
| Elevated Troponin I           | 116/762 (15) | 115/1274 (9) | <0.001 | 117/733 (16) | 114/1303 (9) | <0.001 |
| Complications                 | 232 (21) | 212 (12) | <0.001 | 236 (21) | 208 (12) | <0.001 |
| mRS > 2 at discharge          | 685 (61) | 794 (45) | <0.001 | 691 (63) | 788 (44) | <0.001 |

**Abbreviations:** BI Barthel index, LOS Length of stay, mRS modified Rankin Scale, NIHSS National Institutes of Health Stroke Scale, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, SII systemic immune-inflammation index

Data are expressed as n (%)
Table 3 Mean values of the four immuno-inflammatory markers in groups divided according to the TOAST classification

| TOAST classification                      | Mean age (years) | NIHSS on admission | SII      | NLR      | PLR      |
|------------------------------------------|------------------|--------------------|----------|----------|----------|
| Transient ischemic attack (n = 475)      | 71.0±13.5        | -                  | 772±1048 | 3.8±5.9  | 142±103  |
| Small vessel occlusion (n = 1365)        | 68.8±13.5        | 4.5±4.1            | 771±810  | 3.5±3.4  | 139±91   |
| Large artery atherosclerosis (n = 935)   | 71.8±13.4        | 9.7±8.7            | 979±1451 | 4.6±5.9  | 150±136  |
| Cardioembolism (n = 460)                | 76.2±11.9        | 12.0±10.0          | 994±1682 | 5.0±7.9  | 150±122  |
| Other determined etiology (n = 43)       | 67.2±17.0        | 8.4±8.3            | 1755±4839| 6.9±14.0 | 209±317  |
| Undetermined etiology (n = 100)          | 69.9±14.1        | 9.7±9.3            | 903±1088 | 4.5±6.1  | 145±119  |
| *P* value                                | *<0.001*         | *<0.001*           | *<0.001* | *<0.001* | 0.002    |

Abbreviations: NC neutrophil counts, NIHSS National Institutes of Health Stroke Scale, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, SII systemic immune-inflammation index, TOAST Trial of ORG 10172 in Acute Stroke Treatment

Table 4 Univariate analysis of the predictors of unfavorable outcomes (modified Rankin Scale score >2)
| Variables                                      | Odds ratio | 95 % CI       |
|------------------------------------------------|------------|---------------|
| Age (years)                                    | 1.051      | 1.044-1.057   |
| Hemoglobin (g/dL)                              | 0.837      | 0.807-0.869   |
| Platelet (10^9/L)                              | 0.999      | 0.998-1.000   |
| White blood cells (× 10^3/mL)                  | 1.000      | 1.000-1.000   |
| Neutrophil counts (× 10^3/mL)                  | 1.134      | 1.100-1.170   |
| Systemic immune inflammation index             | 1.000      | 1.000-1.001   |
| Neutrophil-to-lymphocyte ratio                 | 1.140      | 1.109-1.172   |
| Platelet-to-lymphocyte ratio                   | 1.003      | 1.002-1.003   |
| Glucose (mg/dL)                                | 1.001      | 1.000-1.002   |
| Creatinine (mg/dL)                             | 1.168      | 1.088-1.254   |
| Cholesterol (mg/dL)                            | 0.997      | 0.995-0.999   |
| Triglyceride (mg/dL)                           | 0.998      | 0.997-0.998   |
| Length of stay (days)                          | 1.164      | 0.149-1.178   |
| NIHSS score on admission                       | 1.451      | 1.405-1.498   |
| Female sex                                     | 1.802      | 1.553-2.091   |
| Hypertension                                   | 1.267      | 1.076-1.492   |
| Diabetes Mellitus                              | 1.378      | 1.183-1.606   |
| Hyperlipidemia                                 | 0.640      | 0.532-0.771   |
| Heart disease                                  | 1.789      | 1.522-2.104   |
| Prior stroke                                   | 1.490      | 1.258-1.766   |
| Current smoker                                 | 0.471      | 0.391-0.567   |
| Alcohol consumption                            | 0.560      | 0.424-0.739   |
| History of cancer                              | 1.985      | 1.465-2.689   |
| Uremia                                         | 2.874      | 1.741-4.745   |
| Elevated Troponin I                            | 3.896      | 2.897-5.241   |
| In-hospital complications                      | 21.183     | 14.141-31.733 |

**Abbreviations:** NIHSS National Institutes of Health Stroke Scale

Data are expressed as mean ± standard deviation or n (%); two sample t or chi-square test

Table 5 Logistic model of the influence of factors along with the immuno-inflammatory markers on unfavorable outcomes
| Variables                     | Unfavorable outcome (mRS > 2) with SII |  | Unfavorable outcome (mRS > 2) with NLR |  |
|-------------------------------|---------------------------------------|---|--------------------------------------|---|
|                               | OD (95% CI)                           | P value | OD (95% CI)                           | P value |
| Age > 75 years                | 2.650 (2.067-3.399)                   | <0.001  | 2.539 (1.979-3.257)                   | <0.001  |
| Female sex                    | 1.403 (1.088-1.809)                   | 0.009   | 1.459 (1.311-1.882)                   | 0.00C   |
| Hypertension                  | 0.989 (0.757-1.293)                   | 0.938   | 0.986 (0.754-1.289)                   | 0.91    |
| Diabetes mellitus             | 1.561 (1.214-2.008)                   | <0.001  | 1.586 (1.233-2.040)                   | <0.001  |
| Hyperlipidemia                | 0.846 (0.626-1.142)                   | 0.275   | 0.871 (0.645-1.175)                   | 0.36    |
| Heart disease                 | 1.340 (1.038-1.729)                   | 0.025   | 1.301 (1.009-1.678)                   | 0.04    |
| Prior stroke                  | 1.316 (1.008-1.717)                   | 0.043   | 1.299 (0.996-1.694)                   | 0.05    |
| Current smoker                | 0.807 (0.577-1.128)                   | 0.209   | 0.796 (0.570-1.112)                   | 0.18    |
| Alcohol consumption           | 0.961 (0.598-1.547)                   | 0.871   | 0.940 (0.583-1.514)                   | 0.79    |
| History of cancer             | 1.423 (0.894-2.266)                   | 0.137   | 1.359 (0.853-2.165)                   | 0.19    |
| Uremia                        | 1.757 (0.824-3.742)                   | 0.144   | 1.723 (0.807-3.682)                   | 0.16    |
| Elevated troponin I           | 1.875 (1.272-2.765)                   | 0.002   | 1.872 (1.267-2.767)                   | 0.00C   |
| NIHSS (admission) ≥ 5         | 13.934 (11.001-17.648)                | <0.001  | 13.863 (10.948-17.553)                | <0.00C  |
| SII > 724                     | 1.808 (1.422-2.297)                   | <0.001  | -                                     | -       |
| NLR > 3.5                     | -                                     | -       | 1.761 (1.382-2.243)                   | <0.00C  |
| PLR > 143                     | -                                     | -       | -                                     | -       |
| NC > 6 (× 10^3/mL)            | -                                     | -       | -                                     | -       |

**Abbreviations:** CI confidence interval, mRS modified Rankin Scale, NC neutrophil counts, NIHSS National Institutes of Health Stroke Scale, NLR neutrophil-to-lymphocyte ratio, OD odds ratio, PLR platelet-to-lymphocyte ratio, SII systemic immune-inflammation index

Table 6 C-statistics of the basic model with various immuno-inflammatory markers for the prediction of unfavorable outcome
| Variables                                                      | Unfavorable outcome (mRS >) |
|---------------------------------------------------------------|-----------------------------|
|                                                               | C-statistics (95% CI)       | P   |
| Basic model with 7 predictors a                               | 0.860 (0.843-0.876)         | -   |
| Plus systemic immune-inflammatory index > 724                | 0.864 (0.847-0.880)         | 0.0  |
| Plus neutrophil-to-lymphocyte ratio > 3.5                    | 0.863 (0.847-0.880)         | 0.0  |
| Plus platelet-to-lymphocyte ratio > 143                      | 0.863 (0.846-0.880)         | 0.0  |
| Plus neutrophil counts > 6 (× 10³/mL)                        | 0.861 (0.845-0.879)         | 0.1  |
| Plus all above four markers                                   | 0.864 (0.848-0.881)         | 0.0  |

*Abbreviations: CI confidence interval

a Including National Institute of Health Stroke Scale score ≥ 5, age > 75 years, diabetes mellitus, elevated troponin I level, female sex, heart disease, and prior stroke

*Compared with the basic model

Figures
Figure 1

C-statistic of the basic model for the seven significant predictors of unfavorable outcome;

predictive performance of 0.860. HD: heart disease

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
Datasets-2903Pt.xlsx